scholarly journals Postrenal Transplant Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy Associated with Parvovirus B19 Infection

2008 ◽  
Vol 8 (6) ◽  
pp. 1340-1344 ◽  
Author(s):  
M. R. Ardalan ◽  
M. M. Shoja ◽  
R. S. Tubbs ◽  
H. Esmaili ◽  
H. Keyvani
2014 ◽  
Vol 124 ◽  
pp. 438-441 ◽  
Author(s):  
Michinori Mayama ◽  
Masato Yoshihara ◽  
Tetsuya Kokabu ◽  
Hidenori Oguchi

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
C. J. Steffen ◽  
N. Koch ◽  
K. U. Eckardt ◽  
K. Amann ◽  
E. Seelow ◽  
...  

Abstract Background Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disease characterized by hyperactivation of the immune system that causes hypercytokinemia and potentially multi organ failure. HLH can occur in patients with underlying rheumatic or autoinflammatory disorders. Additionally, HLH can develop in patients during infections or malignancies without a known genetic predisposition. Case presentation We herein report a patient, who presented with fever, both acute kidney and liver injury, anemia, thrombocytopenia and HSV stomatitis. HLH was diagnosed based on clinical criteria and qPCR revealed an acute parvovirus B19 infection as potential underlying infectious trigger. Treatment was started with both IVIG and dexamethasone. Subsequently, kidney biopsy demonstrated TMA. Conclusions In rare cases both HLH and aHUS can occur simultaneously in a patient as a consequence of viral infections. Insights from this unusual case might help physicians understand this complex symptom constellation.


2007 ◽  
Vol 28 (5) ◽  
pp. 394-395 ◽  
Author(s):  
C. J. McMahon ◽  
H. Murchan ◽  
T. Prendiville ◽  
M. Burch

Blood ◽  
2000 ◽  
Vol 96 (3) ◽  
pp. 1184-1186 ◽  
Author(s):  
Vivek R. Sharma ◽  
Donald R. Fleming ◽  
Stephen P. Slone

Abstract Rituximab is a chimeric monoclonal antibody directed against CD20 and used in the treatment of B-cell non-Hodgkin's lymphoma. Due to its ability to deplete B lymphocytes, rituximab can interfere with humoral immunity, causing it to be suppressed for several months after treatment. The reported case depicts a serious consequence of this effect of rituximab therapy: pure red cell aplasia resulting from chronic parvovirus B19 infection. The point of interest in this case is not only the association between rituximab therapy and pure red cell aplasia, but the diagnostic and therapeutic utility of the knowledge of parvovirus B19 as the likely etiologic link between the two. Given the known efficacy of intravenous immunoglobulin (IVIg) in the treatment of chronic parvovirus B19 infection, this therapy can cure some of these patients and successfully render most others transfusion-independent until recovery of their own humoral immune system.


2009 ◽  
Vol 40 (7) ◽  
pp. 612-617 ◽  
Author(s):  
Shih-Chi Liu ◽  
Chia-Ti Tsai ◽  
Cho-Kai Wu ◽  
Meng-Fen Yu ◽  
Mu-Zon Wu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document